Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study

The Egyptian Journal of Internal Medicine

Table 2 Comparison between Gp1 and Gp2 parameters after 12th week of treatment

Parameter	Gp1 (n = 58)	Gp2 (n = 81)	P-value
ALT (IU/L)	17 (4–55)	18 (4–59)	0.894
AST (IU/L)	22.5 (10–60)	24 (6–64)	1.000
Albumin, g/dl	4 (2.7–5)	4.1 (2.6–5.3)	0.609
Total bilirubin, mg/dl	0.9 (0.3–3)	0.9 (0.2–3.7)	0.624
WBCs, 10⁹/L	5.9 (2.5–17)	6.2 (3–13)	0.454
HB (%)	12.6 (5.9–15.2)	12.0 (7.0–16.5)	0.344
Creatinine, mg/dl	0.9 (0.5–1.3)	0.9 (0.5–1.4)	1.000
Platelet, 10⁹/L	203 (100–453)	212 (100–441)	0.824

Values are presented as median (range)
ALT alanine aminotransferase, AST aspartate aminotransferase, WBCs white blood cells, HB hemoglobin, P value ≤ 0.05 is considered significant
Gp1 received sofosbuvir 400 mg/day plus daclatasvir 60 mg/day plus simeprevir 150 mg/day plus ribavirin 15 mg/kg/day for 12 weeks
Gp2 received sofosbuvir 400 mg/day plus ombitasvir 25 mg, paritaprevir 150 mg, and ritonavir 100 mg/day plus ribavirin 15 mg/kg/day for 12 weeks